Related Experiment Video
Updated: Dec 18, 2025
12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
10.8K
Emerging treatments for bullous pemphigoid
Pedro Miguel Garrido1, Catarina Soares QueiróS1, Ana Rita Travassos1
1Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (CHULN), Lisbon, Portugal.
The Journal of Dermatological Treatment
|June 16, 2020
Summary
Bullous pemphigoid (BP), an autoimmune blistering disease, is increasingly affecting the elderly. Novel targeted therapies offer safer and more effective alternatives to current treatments like corticosteroids.
Area of Science:
- Dermatology
- Immunology
- Autoimmune Diseases
Background:
- Bullous pemphigoid (BP) is the most prevalent autoimmune blistering dermatosis.
- It involves an immune attack on hemidesmosomal proteins BP180 and BP230.
- BP incidence is rising, primarily affecting the elderly population.
Purpose of the Study:
- To review current evidence on novel targeted therapies for bullous pemphigoid.
- To explore emerging treatments that address specific pro-inflammatory mediators in BP.
- To highlight safer and more efficient alternatives to conventional BP treatments.
Main Methods:
- Literature review of recent advances in bullous pemphigoid pathogenesis.
- Analysis of studies investigating novel therapeutic agents for BP.
- Discussion of targeted approaches against pro-inflammatory mediators in BP.
Main Results:
- Current treatments (corticosteroids, immunosuppressants) carry significant risks with long-term use.
- Newer therapies targeting specific inflammatory pathways show promise.
- These novel treatments are expected to offer improved efficacy and safety profiles.
Conclusions:
- Targeted therapies represent a significant advancement in bullous pemphigoid management.
- These innovative treatments may reduce the morbidity and mortality associated with long-term immunosuppression.
- Further research and clinical application of novel agents are anticipated for BP treatment.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
355
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
355
01:30Skin Cancer
5.6K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.6K
01:26Peptic Ulcer Disease IV: Management
326
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
326
01:19Clinical Applications of Epidermal Stem Cells
3.1K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.1K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
344
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
344
01:27Tumor Immunotherapy
1.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K